Peripheral artery disease: therapeutic advances

References

• Hirsch AT et al. Perpheral arterial disease detection, awareness and treatment in primary care. JAMA286, 1317–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Wang JC, Criqui MH, Denenberg JO, McDermott MM, Golomb BA, Fronek A. Exertional leg pain in patients with and without peripheral arterial disease. Circulation112(22), 3501–3508 (2005).
   PubMed Web of Science ®Google Scholar
• McDermott MM, Greenland P, Liu K et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA286(13), 1599–606 (2001).
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg.45(Suppl. S), S5–S67 (2007).
   PubMed Web of Science ®Google Scholar
• Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med.344(21), 1608 (2001).
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med.326(6), 381–386 (1992).
   PubMed Web of Science ®Google Scholar
• Aboyans V, Lacroix P, Guilloux J et al. A predictive model for screening cerebrovascular disease in patient undergoing coronary artery bypass grafting. Interact. Cardiovasc. Thorac. Surg.4(2), 90–95 (2005).
   PubMedGoogle Scholar
• Aboyans et al. Subclinical peripheral arterial disease and incomplete ankle arteries are both long term prognostic factors in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol.46(5), 815–820 (2005).
   PubMed Web of Science ®Google Scholar
• Cardiovascular Heart Study (CHS) Collaborative Research Group. Ankle–arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation88(3), 837–845 (1993).
   Google Scholar
• McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis87(2–3), 119–128 (1991).
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med.326(6), 381–386 (1992).
   PubMed Web of Science ®Google Scholar
• Resnick et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation109(6), 733–739 (2004).
   PubMed Web of Science ®Google Scholar
• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation110(6), 738–743 (2004).
   PubMed Web of Science ®Google Scholar
• Diehm C, Lange S, Darius H et al. Association of low ankle brachial index with high mortality in primary care. Eur. Heart J.27(14), 1743–1749 (2006).
   PubMed Web of Science ®Google Scholar
• Peripheral Arterial Disease: ACC/AHA 2005 guidelines for the management of patients with (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the AAVS/SVS, SCAI, SVMB, SIR, and the ACC/AHA Task Force on Practice Guidelines.
   Google Scholar
• Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med. Sci. Sports Exerc.23(4), 402–408 (1991).
   PubMed Web of Science ®Google Scholar
• Baum RA, Rutter CM, Sunshine JH. Multicenter Trial to evaluate vascular magnetic resonance angiographyof the lower extremity. American College of Radiology Rapid Technology Assessment Group. JAMA274(11), 875–880 (1995).
   PubMed Web of Science ®Google Scholar
• Prince MR, Chabra SG, Watts R et al. Contrast material travel times in patients undergoing peripheral MR angiography. Radiology224(1), 55–61 (2002).
   PubMed Web of Science ®Google Scholar
• Rubin GD, Shiau MC, Leung AN, Kee ST, Logan LJ, Sofilos MC. Aorta and iliac arteries: single versus multiple detector-row helical CT angiography. Radiology215(3), 670–676 (2000).
   PubMed Web of Science ®Google Scholar
• Rubin GD, Schmidt AJ, Logan LJ, Sofilos MC. Multi-detector row CT angiography of lower extremity arterial inflow and runoff: initial experience. Radiology221(1), 146–158 (2001).
   PubMedGoogle Scholar
• Gardener AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA274(12), 975–980 (1995).
   PubMed Web of Science ®Google Scholar
• Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc. Med.2(3), 238–242 (1997).
   PubMedGoogle Scholar
• Robeer GG, Brandsma JW, van den Heuvel SP, Smit B, Oostendorp RA, Wittens CH. Exercise therapy for intermittent claudication: a review of the quality of randomized clinical trials and evaluation of predictive factors. Eur. J. Vasc. Endovasc. Surg.15(1), 36–43 (1998).
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Ferrucci L et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann. Intern. Med.144(1), 10–20 (2006).
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation90(4), 1866–1874 (1994).
   PubMed Web of Science ®Google Scholar
• Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N. Engl. J. Med.347(24), 1941–1951 (2002).
   PubMed Web of Science ®Google Scholar
• Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br. J. Surg.69(Suppl.), S24–S26 (1982).
   PubMedGoogle Scholar
• Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J. Vasc. Surg.42(1), 67–74 (2005).
   PubMed Web of Science ®Google Scholar
• Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med. J. Aust.1(5), 217–219 (1993).
   Google Scholar
• Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxyfylline, or nafronyl: a meta-analysis. Arch. Intern. Med.159(4), 337–345 (1999).
   PubMed Web of Science ®Google Scholar
• Tsai ST, Cho HJ, Cheng HS et al. A randomized, placebo-controlled trial of varenicline, a selective a4b2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin. Ther.29(6), 1027–1039 (2007).
   PubMed Web of Science ®Google Scholar
• Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol.75(14), 894–903 (1995).
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. (UKPDS 33). Lancet352(9131), 837–853 (1998).
   Google Scholar
• Giri J, McDermott MM, Greenland P et al. Statin use and functional decline in patients with and without peripheral arterial disease. J. Am. Coll. Cardiol.47(5), 998–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Abbruzzese TA, Havens J, Belkin M et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J. Vasc. Surg.39(6), 1178–1185 (2004).
   PubMed Web of Science ®Google Scholar
• Poldermans D, Bax JJ, Kertai MD et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation107(14), 1848–1851 (2003).
   PubMed Web of Science ®Google Scholar
• Durazzo AE, Machado FS, Ikeoka DT et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J. Vasc. Surg.39(5), 967–975 (2004).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation108(12), 1481–1486 (2003).
   PubMed Web of Science ®Google Scholar
• Mondillo S, Ballo P, Barbati R et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am. J. Med.114(5), 359–364 (2003).
   PubMed Web of Science ®Google Scholar
• Abela GS, Aziz K Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin. Cardiol.28(9), 413–420, (2005).
   PubMed Web of Science ®Google Scholar
• Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events – a novel insight into plaque rupture by scanning electron microscopy. Scanning28, 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Abela GS, Aziz K, Huang R, Delong J. Statins inhibit Cholesterol Crystallization and Prevent Perforation of Biological Membranes and Intima in Human Coronary Arteries of Patients with Acute Coronary Syndrome. J. Am. Coll. Card.49, 358A (2007).
   PubMed Web of Science ®Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324(7329), 71–86 (2002).
   Google Scholar
• CAPRIE Steering Committee. Arandomised , blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348(9038), 1329–1339 (1996).
   Google Scholar
• Bhatt DL, Flather MD, Hacke W et al. CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol.49(19), 1982–1988 (2007).
   PubMed Web of Science ®Google Scholar
• Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. An international anticoagulant review group. Lancet1(7640), 203–209 (1970).
   Google Scholar
• Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med.323(3), 147–152, (1990).
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch. Intern. Med.157(21), 2413–2446 (1997).
   Google Scholar
• Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann. Intern. Med.144(9), 660–664 (2006).
   PubMed Web of Science ®Google Scholar
• Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency: a complication of β-adrenergic blocking therapy. JAMA208(13), 2471–2472 (1969).
   PubMed Web of Science ®Google Scholar
• Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. b blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ303(6810), 1100–1104 (1991).
   PubMed Web of Science ®Google Scholar
• Radack K, Deck C. β adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta analysis of randomized control trials. Arch. Intern. Med.151(9), 1769–1776 (1991).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Feringa HH, van Waning VH, Bax JJ et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J. Am. Coll. Cardiol.47(6), 1182–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med.338(15), 1042–1050 (2000).
   Web of Science ®Google Scholar
• Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular diease. The European Concerted Action Project. JAMA277(22), 1775–1781 (1997).
   PubMed Web of Science ®Google Scholar
• Westendorp IC, in’t Veld BA, Grobbee DE et al. Hormone Replacement Therapy and peripheral arterial disease: The Rotterdam study. Arch. Inern. Med.160(16), 2498–2502 (2000).
   PubMed Web of Science ®Google Scholar
• Regensteiner J, Ware JJ, McCarthy W et al. Effect of cilostazol on treadmill walking, community-based walking ability and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J. Am. Geriatr. Soc.50(12), 1939–1946 (2002).
   PubMed Web of Science ®Google Scholar
• Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxyfylline for treating intermittent claudication. Am. J. Med.109(7), 523–530 (2000).
   PubMed Web of Science ®Google Scholar
• Pratt C. Analysis of cilostazol safety database. Am. J. Cardiol.87(12A), 28D–33D (2001).
   Google Scholar
• Kim JY, Lee K, Shin M et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ. J.71(12), 1867–1872 (2007).
   PubMed Web of Science ®Google Scholar
• Samlaska CP, Winnfield EA. Pentoxyifylline. J. Am. Acad. Dermatol.30(4), 603–621 (1994).
   PubMed Web of Science ®Google Scholar
• Jaff MR. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options. Angiology53(6), 627–633 (2002).
   PubMed Web of Science ®Google Scholar
• Carman TL, Fernandez BB Jr. Contemporary management of peripheral arterial disease: II. Improving walking distance and quality of life. Cleve. Clin. J. Med.73(Suppl. 4), S38–S44 (2006).
   Google Scholar
• Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch. Intern. Med.159(4), 337–345 (1999).
   PubMed Web of Science ®Google Scholar
• Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ155(8), 1053–1059 (1996).
   PubMed Web of Science ®Google Scholar
• Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J. Cardiovasc. Pharmacol.23(Suppl. 3), S48–S52 (1994).
   PubMedGoogle Scholar
• Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann. Cardiol. Angeiol. (Paris)50(3), 175–182 (2001).
   PubMedGoogle Scholar
• Kieffer E, Bahnini A, Mouren X and Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int. Angiol.20(1), 58–65 (2001).
   PubMed Web of Science ®Google Scholar
• Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int. Angiol.21(1), 20–27 (2002).
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Fatuzzo P, Rapisarda F et al. A randomized controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl l-carnitine in patients with peripheral arterial disease requiring hemodialysis. Drugs Aging23(3), 263–270 (2006).
   PubMed Web of Science ®Google Scholar
• Brevetti G, Diehm C, Lambert D. European Multicenter studies on Propionyl-l-carnitine in intermittent claudication. J. Am. Coll. Cardiol.34(5), 1618–1624 (1999).
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Regensteiner J, Creager M et al. Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am. J. Med.110(8), 616–622 (2001).
   PubMed Web of Science ®Google Scholar
• Coffman J. Vasodilator drugs in peripheral vascular disease. N. Engl. J. Med.301(3), 713–717 (1979).
   Google Scholar
• De Backer T, Vander Stichele R, Bogaert M. Buflomedil for intermittent claudication. Cochrane Database Syst. Rev. (2001).
   PubMedGoogle Scholar
• De Backer T, Vander Stichele R, Warie H, Bogaert M. Oral vasoactive medication in intermittent claudication: utile or futile? Eur. J. Clin. Pharmacol.56(3), 199–206 (2000).
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Mohler EI, Lederman R et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation108(16), 1933–1938 (2003).
   PubMed Web of Science ®Google Scholar
• Lederman R, Mendelsohn F, Anderson R et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (The TRAFFIC study): a randomized trial. Lancet9323, 2053–2058 (2002).
   Google Scholar
• Therapeutic Angiogenesis With Intramuscular NV1FGF in Patients With Critical Limb Ischemia (TALISMAN) 2006. Summary posted 3/12/2006. (2006).
   Google Scholar
• Liu PQ, Rebar EJ, Zhang L et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem.276, 11323–11334 (2001).
   PubMed Web of Science ®Google Scholar
• Dai Q, Huang J, Klitzman B et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation110, 2467–2475 (2004).
   PubMed Web of Science ®Google Scholar
• Rebar EJ, Huang Y, Hickey R et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med.8, 1427–1432 (2002).
   PubMed Web of Science ®Google Scholar
• Xie D, Li Y, Reed EA et al. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J. Vasc. Surg.44, 166–175 (2006).
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Olin J, Deitcher S et al. Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation115, 1234–1243 (2007).
   PubMed Web of Science ®Google Scholar
• Yamakawa M, Liu LX, Date T et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res.93, 664–673 (2003).
   PubMed Web of Science ®Google Scholar
• Murohara T, Ikeda H, Duan J et al., Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest.105, 1527–1536 (2000).
   PubMed Web of Science ®Google Scholar
• Kalka, C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA973422–3427 (2000).
   PubMed Web of Science ®Google Scholar
• Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr. Vasc. Pharmacol.5(3), 195–209 (2007).
   PubMed Web of Science ®Google Scholar
• Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet360, 427–435 (2002).
   PubMed Web of Science ®Google Scholar
• Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by L-Arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J. Am. Coll. Cardiol.32(5), 1336–1344 (1998).
   PubMed Web of Science ®Google Scholar
• Maxwell AJ, Anderson BE and Cooke JP. Nutritional therapy for peripheral arterial disease: a souble blind, placebo controlled, randomized trial of HeartBar. Vasc. Med.5(1), 11–19 (2000).
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Klepack E, Nehler M et al. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vasc. Med.9(4), 271–277 (2004).
   PubMed Web of Science ®Google Scholar
• Norgren L, Jawien A, Matyas L, Rieger H, Arita K. The European MCI-9042 Study Group. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European Study.Vasc. Med.11(2), 75–83 (2006).
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Higashi Y, Goto C et al. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J. Cardiovasc. Pharmacol.49(4), 221–227 (2007).
   PubMed Web of Science ®Google Scholar
• Thulesius O, Lundwall J, Kroese A et al. Ketanserin in intermittent claudication: effect on walking distance, blood pressure and cardiovascular complications. J. Cardiovasc. Pharmacol.9(6), 728–733 (1987).
   PubMed Web of Science ®Google Scholar
• Nehler MR, Brass EP, Anthony R et al. Circulase investigators. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J. Vasc. Surg.45(5), 953–960 (2007).
   PubMed Web of Science ®Google Scholar
• Belch J, Bell P, Creissen D et al. Randomised, placebo-controlled double blind study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation95(9), 2298–2303 (1997).
   PubMed Web of Science ®Google Scholar
• Creager M, Dzau V and Loscalzo J. Vascular Medicine - A Companion to Braunwald’s Heart Disease. WB Saunders (2006).
   Google Scholar
• Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittents (BERCI) Research Group. Circulation102(4), 426–431 (2000).
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Hiatt WR, Olin J, Wade M, Jeffs R, Hirsch A. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J. Am. Coll. Cardiol.41(10), 1679–1686 (2003).
   PubMed Web of Science ®Google Scholar
• Delis KT, Nicolaides AN, Wolfe JH, Stansby G. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic compression: a prospective controlled study with one-year followup. J. Vasc. Surg.31(4), 650–651 (2000).
   PubMed Web of Science ®Google Scholar
• Gaskell P, Parrott JC. The effect of a mechanical venous pump on the circulation of the feet in the presence of arterial obstruction. Surg. Gynecol. Obstet.146(4), 583–592 (1978).
   PubMedGoogle Scholar
• Morgan RH, Carolan G, Saila JV et al. Arterial flow enhancement by impulse compression. Vasc. Surg.25, 8–15 (1991).
   Google Scholar
• Delis KT, Labropoulos N, Nicolaides AN, Glenville B, Stansby G. The effect of intermittent pneumatic foot compression on popliteal artery hemodynamics. Eur. J. Vasc. Endovasc. Surg.19(3), 270–278 (2000).
   PubMed Web of Science ®Google Scholar
• Delis KT, Azizi ZA, Stevens RJ, Wolfe JH, Nicolaides AN. Determining the optimum intermittent pneumatic compression stimulus for lower limb venous emptying using direct pressure measurements. Eur. J. Vasc. Endovasc. Surg.19(3), 261–270 (2000).
   PubMed Web of Science ®Google Scholar
• Delis KT, Nicolaides AN, Wolfe JH, Stansby G. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic compression: a prospective controlled study with one-year followup. J. Vasc. Surg.31(4), 650–651 (2000).
   PubMed Web of Science ®Google Scholar
• Laurora G, Ambrosoli L, Cesarone MR et al. Treatment of intermittent claudicaiton with defibrotide or mesoglycan. A double blind study. Panminerva Med.36(2), 83–86 (1994).
   PubMed Web of Science ®Google Scholar
• Strano A, Fareed J, Sabba C et al. A double blind multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin. Thromb. Hemost.17(Suppl. 2), 228–234 (1991).
   PubMed Web of Science ®Google Scholar
• Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication – results of a randomized, placebo-controlled study ( the DICLIS study). Defibrotide Intermittent Claudication Italian Study. Thromb. Haemost.83(5), 672–677 (2000).
   PubMed Web of Science ®Google Scholar
• Niezgoda JA, Mewissen M. The management of lower extremity wounds complicated by acute arterial insufficiency and ischemia. Ostomy Wound Manage.50(5A Suppl.), 1–11 (2004).
   PubMedGoogle Scholar
• Vincenzo S, Kyventidis T. Epidural spinal cord stimulation in lower limb ischemia. Acta. Neurochir. Suppl.97(Pt 1), 253–258 (2007).
   PubMedGoogle Scholar
• Ouriel K. Peripheral arterial disease. Lancet358, 1257 (2001).
   PubMed Web of Science ®Google Scholar
• Pell P. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur. J. Vasc. Endovasc. Surg.9, 469 (1995).
   PubMed Web of Science ®Google Scholar
• Currie IC, Wilson YG, Baird RN et al. Treatment of intermittent claudication: The impact on quality of life. Eur. J. Vasc. Endovasc. Surg.10, 356 (1995).
   PubMed Web of Science ®Google Scholar
• Zannetti S, L’Italien GJ, Cambria RP. Functional outcome after surgical treatment for intermittent claudication. J. Vasc. Surg.24, 65 (1996).
   PubMed Web of Science ®Google Scholar
• Matsi PJ, Manninen, HI, Vanninen, RL et al. Femoropopliteal angioplasty in patients with claudication: Primary and secondary patency in 140 limbs with 1–3 year follow-up. Radiology191, 727 (1994).
   PubMed Web of Science ®Google Scholar
• Capek P, McLean, GK, Berkowitz, HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation83, I70 (1991).
   Web of Science ®Google Scholar
• Taylor LM Jr, Porter JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation83(Suppl.), I-63–I-69 (1991).
   Web of Science ®Google Scholar
• Slovut DP and Demaioribus CA. Hybrid revascularization using Silverhawk atherectomy and infrapopliteal bypass for limbs. Ann. Vasc. Surg.21(6), 796–800 (2007).
   PubMed Web of Science ®Google Scholar
• Zeller T, Sixt S, Schwarzwälder U et al. Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device. J. Endovasc. Ther.14(2), 232–240 (2007).
   PubMed Web of Science ®Google Scholar
• Abela GS. Innovations in laser applications in the cardiovascular field. Keio J. Med.42(4), 164 (1993).
   PubMedGoogle Scholar